- Home
- IDAI vs XBIO Comparison
IDAI vs XBIO Comparison
Compare IDAI & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- XBIO
- Stock Information
- Founded
- IDAI 2016
- XBIO N/A
- Country
- IDAI United States
- XBIO United States
- Employees
- IDAI N/A
- XBIO N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- XBIO Health Care
- Exchange
- IDAI Nasdaq
- XBIO Nasdaq
- Market Cap
- IDAI 5.5M
- XBIO 5.8M
- IPO Year
- IDAI N/A
- XBIO N/A
- Fundamental
- Price
- IDAI $1.99
- XBIO $2.72
- Analyst Decision
- IDAI
- XBIO Hold
- Analyst Count
- IDAI 0
- XBIO 1
- Target Price
- IDAI N/A
- XBIO N/A
- AVG Volume (30 Days)
- IDAI 85.8K
- XBIO 9.9K
- Earning Date
- IDAI 05-13-2025
- XBIO 05-08-2025
- Dividend Yield
- IDAI N/A
- XBIO N/A
- EPS Growth
- IDAI N/A
- XBIO N/A
- EPS
- IDAI N/A
- XBIO N/A
- Revenue
- IDAI $3,082,348.00
- XBIO $2,500,284.00
- Revenue This Year
- IDAI $65.46
- XBIO $14.23
- Revenue Next Year
- IDAI N/A
- XBIO N/A
- P/E Ratio
- IDAI N/A
- XBIO N/A
- Revenue Growth
- IDAI N/A
- XBIO N/A
- 52 Week Low
- IDAI $0.15
- XBIO $2.20
- 52 Week High
- IDAI $8.96
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- IDAI 55.69
- XBIO 48.09
- Support Level
- IDAI $1.43
- XBIO $2.32
- Resistance Level
- IDAI $1.77
- XBIO $2.61
- Average True Range (ATR)
- IDAI 0.19
- XBIO 0.15
- MACD
- IDAI 0.06
- XBIO 0.07
- Stochastic Oscillator
- IDAI 100.00
- XBIO 99.83
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.